$PACK

Ranpak (NYSE:PACK) Reaches New 1

Ranpak Holdings (NYSE:PACK) hit a new 52-week high on Tuesday, trading up to $6.67 and last at $6.62 versus a prior close of $6.28. The article cites recent analyst actions including UBS and Cantor reiterating “overweight,” while Wall Street Zen raised PACK to “hold.” MarketBeat shows a “Moderate Buy” consensus and $6.83 target. In its April 30 earnings, Ranpak reported EPS of -$0.12 and revenue of $101.2M.

Original reporting
Published May 26, 2026, 10:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 11:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ranpak (NYSE:PACK) Reaches New 1 — source image
Decision brief

The 30-second read

$PACKBullishMed
01

Why it matters

The stock’s new 52-week high is paired with a recent earnings print where EPS missed slightly but revenue beat, plus a consensus Moderate Buy rating.

02

Market read

Traders may treat this as a momentum + sentiment setup, but fundamental profitability remains a key risk.

03

What to watch

High beta (3.06) and negative P/E (losses) imply the stock may react sharply to any earnings-quality concerns not covered here (e.g., guidance, cash flow, backlog).

Relevance 8/10Timing: Immediate (intraday/next-session) due to the new 52-week high and fresh analyst commentary.

Background

Ranpak provides automated systems and consumable paper-based packaging materials as an alternative to plastic void-fill.

Company-level read

Ticker impact

$PACKBullishMedium confidence
Context

Ranpak shares hit a new 52-week high and were last up 6.1%, with recent analyst rating changes and April 30 earnings beat.

Expected impact

Near-term upside bias while price holds above the prior close ($6.28) and the 50-day average ($4.48); volatility likely given high beta (3.06) and negative margins.

Evidence & confidence

The article provides a concrete catalyst (52-week high + earnings beat on revenue) and supportive sentiment (consensus Moderate Buy), but lacks details on forward guidance or new operational events.

Market effects

Supports sentiment for sustainable packaging/paper-based protective packaging demand, though the article is company-specific.

No specific regional catalyst beyond Ranpak’s Ohio headquarters and global operations.

Limited—no international regulatory or macro driver cited; relevance mainly to packaging supply chain sentiment.

Counterpoint

Despite the breakout, Ranpak still shows negative net margin and negative ROE, so the move could fade if investors focus on profitability rather than revenue.

Key entities

  • Ranpak Holdings Corp

    PACK; shares reached a new 52-week high and recently reported April 30 quarterly results.

Related articles

$PACKMed

Ranpak Q2 Earnings Call Highlights

Ranpak (NYSE:PACK) reported Q2 results on an earnings call. Management said constant-currency net revenue rose 15.4% in Europe and Asia-Pacific, with automation revenue up 103.7% and PPS volumes up 2.4% YoY. Adjusted EBITDA increased $2.6M to $19.1M; gross margin improved 150 bps. Ranpak expects automation adjusted EBITDA breakeven late 2026 and EBITDA-positive in 2027.

$PACKMed

Ranpak Holdings Corp. (PACK): Results of Operations and Financial Condition

Ranpak Holdings Corp. (PACK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a04pack-202606xex99x1.htm EX-99.1 Document Exhibit 99.1 Ranpak Holdings Corp. Reports Second Quarter 2026 Financial Results • Net revenue for the second quarter increased 14.0% year over year to $105.2 million and increased 12.2% year over year on a constant currency ba

$TLRYMed

Tilray Posted Record Fiscal 2026 Revenue -- Why Isn't the Stock Rallying?

Tilray Brands reported record fiscal 2026 revenue of $915 million, up 11%, and adjusted EBITDA of $61.1 million, also up 11%. Adjusted net income nearly doubled to $12.2 million, but missed analyst estimates. GAAP net loss was $49.6 million. Management expects fiscal 2027 adjusted EBITDA of $68M-$75M. Cannabis sales represent 29% of total revenue.

$MDTMedAI 8/10

Medtronic vs. Tenet Healthcare: Which Healthcare Stock Offers Better Long-Term Growth?

Medtronic (MDT) and Tenet Healthcare (THC) present distinct growth prospects. MDT reported its highest annual revenue growth in a decade, driven by cardiac ablation solutions and investments in innovation. THC saw a 52.2% increase in adjusted EPS and 6.8% revenue growth, with margin expansion in hospitals. Investors must choose between MDT's innovation-led recovery and THC's operational improvements.